Aromatic-Cationic Peptide Mitigates Mitochondrial Myopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial myopathies are inadequate, with no known cure and limited pharmacological options that fail to completely ameliorate the disorder, leading to significant clinical manifestations and quality of life impairments.
Innovation Solution
Administration of a therapeutically effective amount of the aromatic-cationic peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or its pharmaceutically acceptable salts, such as acetate, tartrate, or hydrochloride, to treat or prevent mitochondrial myopathy symptoms, including various associated diseases and conditions, through oral, intranasal, intrathecally, or other routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacological treatments are used for mitochondrial myopathies, then some symptomatic relief may be achieved, but the treatments fail to completely ameliorate the disorder and no known cure exists
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of aromatic cationic peptides through specific amino acid substitutions (e.g., incorporating D-amino acids, 2',6'-dimethyltyrosine) to enhance mitochondrial targeting and therapeutic efficacy. This structural parameter modification enables the peptide to effectively address mitochondrial myopathy where conventional treatments fail.
Solution Approach 2:
The invention uses composite materials by creating a peptide composition that combines multiple amino acid components with specific properties (aromatic rings, cationic charges, D-configurations) to form a therapeutically effective compound. This composite structure allows the peptide to simultaneously interact with multiple mitochondrial targets and mechanisms.
2Ease of operation
If mitochondrial myopathy is left untreated, then the natural progression of the disease continues with significant clinical manifestations, but conventional treatments provide incomplete amelioration
Solution Approach 1:
The aromatic cationic peptide acts as an intermediary substance that mediates between the administered treatment and the mitochondrial dysfunction. The peptide's specific structure enables it to cross membranes and deliver therapeutic effects directly to mitochondria, bridging the gap between conventional administration and intracellular target.
Solution Approach 2:
The peptide composition demonstrates multi-functionality by addressing multiple aspects of mitochondrial myopathy simultaneously - it targets mitochondrial metabolism, reduces oxidative stress, and improves muscle function. This universal approach allows single administration to address multiple pathological mechanisms.
3Productivity
If aromatic-cationic peptide is administered to treat mitochondrial myopathy, then skeletal muscle function and ATP production are improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The peptide is designed with pre-configured structural features (D-amino acids, aromatic groups, cationic charges) that enable it to automatically target and accumulate in mitochondria upon administration. This preliminary structural preparation eliminates the need for complex delivery systems or multi-step administration protocols.
Solution Approach 2:
The aromatic cationic peptide exhibits self-targeting capability through its inherent structural properties - the cationic groups naturally attract to negatively charged mitochondrial membranes, and the peptide self-accumulates in mitochondria without requiring external guidance systems or complex delivery mechanisms.
Data Source
AI summary
The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.